Immunocore (IMCR) Q3 2026 earnings review
Immunocore's eye cancer sales slow, and its key trial slips
Immunocore, the biotechnology maker of eye cancer drug KIMMTRAK, saw its fifteen-quarter streak of reported sales growth end while its biggest trial readout moved into next year. Reported revenue slipped 1% from a year ago to $102 million as a second-quarter US wholesaler inventory build reversed, though underlying sales grew about 10% after adjusting for US timing quirks. Rising clinical trial spending pushed the company to a $14 million net loss, even as chief executive Bahija Jallal highlighted promising early data combining KIMMTRAK with experimental therapy brenetafusp.
| Underlying revenue growth | ~10% normalizing for Q2 US stocking and 2025 extra week |
|---|---|
| Reported KIMMTRAK sales | $102.2M -1% from a year ago, -12% from Q2 |
| Cash and marketable securities | $901M before ~$120M Q4 rebate payout |
| TEBE-AM Phase 3 readout plan | Pushed to Q2 2027 prior plan: as early as end of 2026 |
⚖️ Verdict: 🔴 Bearish
The story got worse because core eye cancer growth is cooling down at the same time the main catalyst for expansion was pushed back. Completing the 540-patient enrollment for the Phase 3 TEBE-AM skin cancer trial removes recruitment risk, but moving the survival readout from late 2026 to the second quarter of 2027 leaves investors waiting longer while underlying KIMMTRAK growth slows to 10%. On the brighter side, the first type 1 diabetes patient received the company's autoimmune drug, and strong two-drug combination results in eye cancer will launch a new Phase 2/3 trial.
The question now is whether KIMMTRAK can grow faster than 10% a year before the skin cancer trial reads out next spring. One view is that launches in new countries and longer European survival labels still leave room to expand; the other is that roughly 70% patient share in the US caps the drug near current levels. Fourth-quarter sales, free of wholesaler inventory swings, will show the true pace.
🐂 Bull Case
Two-Drug Combination Enters Late-Stage Eye Cancer Trial
Immunocore sells KIMMTRAK, a drug for uveal melanoma, a rare eye cancer that has spread. The biotechnology group is now testing KIMMTRAK alongside brenetafusp, an experimental therapy targeting the PRAME protein found on solid tumors. Chief executive Bahija Jallal said the study delivered "what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor."
- First-line combination response rate: 29% across 17 evaluable patients, with median response lasting 24.1 months
- First-line combination survival: 70% alive at two years, and median progression-free survival of 8.1 months
- Later-line brenetafusp alone: 19% response rate and 20.3-month median survival across 16 patients
Side effects were manageable because no patient suffered severe cytokine release syndrome, an immune overreaction, or stopped treatment due to drug toxicity. That safety record matters because combining two immune-activating drugs could easily overwhelm patients, so the clean results allow the UK and US company to plan a randomized Phase 2/3 trial called DUET-UVEAL.
What to watch: the trial design and start date for DUET-UVEAL, plus ovarian and lung cancer data for brenetafusp due at a medical conference later this year. Clear activity in ovarian or lung tumors would show brenetafusp works outside melanoma.
Diabetes Trial Starts And International Sales Grow
The drugmaker is expanding beyond cancer into autoimmune diseases while pushing KIMMTRAK into new countries. This quarter, the first person with type 1 diabetes received IMC-S118AI, a therapy designed to quiet immune attacks on insulin-producing cells without weakening the whole immune system. Management also plans to file for regulatory permission before year-end to test a second autoimmune drug, IMC-U120AI, for skin conditions like eczema.
Meanwhile, European regulators added KIMMTRAK's five-year survival data to its prescribing label, which will "allow the Company to engage more broadly with healthcare professionals in the region about the data." Sales in international regions outside the US and Europe rose 75.9% from a year ago to $5.1 million, though they dipped from $6.9 million last quarter.
What to watch: the regulatory filing for IMC-U120AI before the end of 2026. Submitting on time would show the autoimmune team can hit deadlines after the diabetes trial started a quarter late.
🐻 Bear Case
Crucial Skin Cancer Readout Slips Into 2027
Immunocore relies on a single Phase 3 trial called TEBE-AM to expand KIMMTRAK into previously treated advanced cutaneous melanoma, a skin cancer pool of up to 4,000 patients in the US and Europe. On the positive side, the trial finally "achieved its target enrollment of 540 patients" this quarter after falling a few weeks behind its original first-half 2026 schedule.
However, the company pushed the timeline for initial survival results back, stating that "topline overall survival data is expected in the second quarter of 2027." For the last three quarters, management had told investors those results could arrive as early as the end of 2026. Because the study waits for a set number of patient deaths to measure survival, slower events can explain the wait, but this marks the fourth clinical timeline to move backward in recent quarters without management calling it a delay.
What to watch: any further change to the second-quarter 2027 readout window in the full-year report. A positive survival result in that window would open a patient group four times larger than the ~1,000 eye cancer patients treated today.
US Sales Drop On Wholesaler Inventory Reversal
"Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma," chief executive Bahija Jallal said. Yet after fifteen straight quarters of top-line expansion, reported net product sales fell 1.4% from a year ago to $102.2 million, and dropped 11.8% from last quarter's $115.9 million.
The company blamed the drop on "United States wholesaler stocking that occurred in Q2 of 2026" — a $6 million inventory build that reversed this quarter — and "one additional week of sales in the U.S. in Q3 2025." Even after adjusting for both items, underlying revenue grew about 10% from a year ago, down from 18% reported growth in the second quarter and 29% across 2025. US sales fell 7.6% from a year ago to $62.2 million because the drug has already reached roughly 70% of eligible US patients.
What to watch: fourth-quarter revenue against last year's $104.5 million, once the wholesaler inventory drag is gone. Growth staying near 10% or lower would confirm the eye cancer market is nearing its ceiling.
Rebate Bill Will Drain Fourth-Quarter Cash
In European countries, Immunocore sells KIMMTRAK at list prices and accrues rebates it must pay back to health authorities later. By our math, operating cash flow rebounded to $20.1 million in the third quarter from just $2.2 million across the entire first half of 2026, helped by accounts receivable falling 7.7% from June to $88.0 million.
That third-quarter cash inflow means the big European rebate bill has not been paid yet. Management previously planned to pay "approximately $120 million in sales-related rebate accruals" during the second half of 2026, and confirmed today the entire sum leaves in the fourth quarter. Because nine-month operating cash flow is only $22.2 million, paying $120 million in rebates will push full-year operating cash flow deep into negative territory.
What to watch: fourth-quarter operating cash flow and the year-end accrued liabilities balance in the annual report. A cash outflow much larger than the rebate bill would show core commercial collections are weakening too.
Risks this quarter didn't answer
Five standing concerns and watch items received no new evidence in the third-quarter earnings release.
- US market penetration rate: missing from the release after sitting near 70% last quarter; the earnings call or quarterly filing must show whether US patient share has stalled.
- Single-product reliance: KIMMTRAK still provides 100% of revenue, leaving the business exposed until TEBE-AM reports in the second quarter of 2027.
- PRAME tumor direction: ovarian and lung cancer data for brenetafusp did not appear in this release and remain due at a conference later in 2026.
- Rival melanoma drugs: competing oral regimens in eye cancer and cell therapies in skin cancer remain clinical threats that only trial readouts will test.
- Convertible debt load: $394.8 million of borrowings sit on the balance sheet while the business posted a $13.6 million quarterly operating loss.
💲 Other KPIs
Immunocore swung back to a wider operating loss after nearly breaking even last quarter. Operating margin fell 6.4 percentage points from a year ago to minus 13.3% by our math, because research and development costs for its three Phase 3 trials rose 5.0 percentage points to 73.1% of revenue and overhead rose 1.2 points to 39.6%.
Total cash and marketable securities rose by $21.1 million from June and $37.1 million since the end of 2025, by our math. After subtracting $394.8 million in loans and borrowings, net cash stands at $506.5 million, giving the drugmaker plenty of cushion to absorb the $120 million fourth-quarter rebate payment.
Basic and diluted shares rose 2.3% from a year ago and 1.1% from the second quarter, by our math. Because the biotech posted a net loss of $14.2 million, stock options and convertible notes were excluded from the diluted count, and dilution came solely from employee share issuances.
🔮 Guidance
Unchanged. Immunocore still expects to pay roughly $120 million in accrued sales rebates, and narrowed the timing from the second half of 2026 specifically to the fourth quarter. Because nine-month operating cash flow was only $22.2 million, this single payout will turn fourth-quarter and full-year operating cash flow negative, nearly double the $65 million paid in late 2025.
Pushed back. With all 540 skin cancer patients now enrolled, the group expects topline survival results in the second quarter of 2027 rather than as early as late 2026. The trial is driven by survival events, and this represents the fourth clinical milestone in recent quarters to move to a later window.
Unchanged. Management still plans to present clinical results from the ovarian and non-small cell lung cancer cohorts at a medical conference before the end of the year. Notably, the release did not repeat the prior target to share initial dose-escalation data for the longer-acting IMC-P115C molecule in the second half of 2026.
Unchanged. The UK and US company remains on track to submit a clinical trial application for its second autoimmune candidate, targeting skin diseases such as atopic dermatitis, before year-end. Its HIV multiple-ascending-dose readout also remains scheduled for early 2027.
❓ Key Questions
Where did US KIMMTRAK patient penetration land in Q3?
The earnings release omitted the US penetration rate after management cited roughly 70% last quarter. Because penetration is the main forward indicator for KIMMTRAK demand, investors need to know if US patient share is still inching up or has hit a ceiling.
Did slower deaths or late enrollment push TEBE-AM to 2027?
Topline survival data moved from as early as late 2026 to the second quarter of 2027 just as enrollment finished. Knowing whether the shift came from the few weeks of enrollment delay or patients living longer in the trial helps judge the odds of success.
When will initial data for IMC-P115C be shared?
Prior filings promised initial Phase 1 data for the longer-acting PRAME drug IMC-P115C in the second half of 2026, but this release only mentioned continuing enrollment. Clarifying that timeline matters for deciding which PRAME molecule leads the franchise.
How much will the DUET-UVEAL trial add to R&D?
Research and development costs already reached 73.1% of revenue this quarter with three Phase 3 trials running. Starting a fourth late-stage trial for the KIMMTRAK and brenetafusp combination will raise quarterly cash burn unless older studies wind down.